Navigation Links
Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting

nically significant."

Study discontinuations due to adverse events occurred in 11 (4.8%) of the 229 Fampridine-SR-treated patients, and none of the 72 patient placebo group. Three of these events were considered serious: influenza, sepsis and anxiety. The anxiety was considered probably related to treatment. A focal seizure, observed during the sepsis, was considered possibly related to treatment. An additional 13 patients in the Fampridine-SR-treated group experienced various serious adverse events but none of these led to discontinuation from treatment and none was considered related to treatment. Most non-serious adverse events were rated as mild to moderate in intensity and observed at similar rates in Fampridine-SR and placebo groups. Some events were seen more frequently in the Fampridine-SR group (insomnia, fatigue, back pain, balance disorder) while upper respiratory infection was more common in the placebo group. Overall, the safety data were consistent with previous experience.

Study Design

The double-blind, placebo-controlled trial was designed to evaluate the safety and efficacy of Fampridine-SR in improving walking ability in people with MS. The trial, which enrolled 301 individuals at 33 MS centers in the United States and Canada, recruited patients between 18 and 70 years old with a definite diagnosis of MS and some degree of walking disability. The study was open to people with all types of MS, including primary-progressive, secondary-progressive, relapsing-remitting and progressive-relapsing. Participants were permitted to remain on a stable regimen of their current medications, including immunomodulators. Secondary endpoints for the trial included the Lower Extremity Manual Muscle Test, the Ashworth Score for spasticity, and Subject and Clinician Global Impressions. Subjects were randomized to 14 weeks of treatment with Fampridine-SR (n=229) or placebo (n=72), a 3:1 ratio of drug to placebo. The safety measures in this trial in
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Acorda Therapeutics Presents Fampridine-SR Data at ACTRIMS Meeting
2. Acorda Therapeutics to Host Analyst and Investor Reception
3. Acorda Therapeutics Presentation of Fampridine-SR Phase 3 Data Selected for Scientific Highlights Program at the American Academy of Neurology Meeting
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
7. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
8. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
9. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
10. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
11. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
Post Your Comments:
(Date:8/20/2014)... August 20, 2014 Phase I ... the US  KalVista Pharmaceuticals ("KalVista"), an ophthalmology ... today announces that it has begun a Phase I, ... inhibitor, KVD001, for the treatment of DME. The study,s ... Beetham Eye Institute, Joslin Diabetes Center; Harvard Medical School ...
(Date:8/19/2014)... 19, 2014 Talyst, a market leader in ... the 2014 NPPA Summer Conference in Las ... its 340B software products and services.   ... supplying over 400 customers with a variety of software ... including its latest solution, AutoSplit® Contract Pharmacy and 340B ...
(Date:8/19/2014)... 2014 /PRNewswire-iReach/ -- ChemImage founder and CTO, Patrick ... describing an innovative diagnostic procedure for the detection of ... on Disease (SPEC) conference in Krakow, Poland ... "Development of in vitro Diagnostics for Detection of Colorectal ... the conference poster session on Tuesday, August 19, 2014 ...
Breaking Medicine Technology:KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4Talyst Exhibits at the NPPA Summer Conference 2ChemImage Scientists Present Latest Developments for in vitro Detection of Colorectal Cancer Using Raman Molecular Imaging (RMI) at International Conference Focused on Biomedical Applications of Raman Spectroscopy 2
... March 15 Sequenom, Inc. (Nasdaq: SQNM ) today reported its financial results for the fourth quarter and year ended December 31, 2009 . , ... , , ... ...   http://www.newscom.com/cgi-bin/prnh/20040415/SQNMLOGO ) , ...
... March 15 International Merchant Advisors, ... today that the company has completed the purchase of ... Inc. in an all stock transaction.  Organic Science, Inc. will ... this business segment, and is focused on the ...
Cached Medicine Technology:Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results 2Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results 3Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results 4Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results 5Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results 6Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results 7Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results 8Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results 9Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results 10Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results 11Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results 12Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results 13Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results 14Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results 15Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results 16International Merchant Advisors Completes All Stock Based Purchase of Medical Marijuana Company Organic Science, Inc. 2International Merchant Advisors Completes All Stock Based Purchase of Medical Marijuana Company Organic Science, Inc. 3
(Date:8/20/2014)... August 20, 2014 It’s no secret ... According to the National Institute on Drug Abuse, nearly ... drugs. What’s even more alarming is the fact that ... last decade. , Those locked in a struggle with ... way out. But now, the newly-redesigned AbuseTreatmentCenters.net has released ...
(Date:8/20/2014)... New York, NY (PRWEB) August 20, 2014 ... the world’s largest nutrition school, is proud to ... of Integral Studies (CIIS), a cutting-edge university ... Integrative Nutrition’s Health Coach Training Program are now ... Master of Arts in Integrative Health Studies. , ...
(Date:8/20/2014)... A Missouri federal judge has remanded a lawsuit filed ... GranuFlo and NaturaLyte to the City of St. Louis Circuit ... The judge rejected an assertion by the defendants that the ... et al. v. Fresenius Medical Care North America Inc., et ... the manufacturer of the dialysis products GranuFlo and NaturaLyte. In ...
(Date:8/20/2014)... 2014 Botanica Day Spa ... Utilizing the new and popular stem cell line ... lines and wrinkles and naturally repairs the skin. ... the new service by offering clients a complimentary ... cell facial. , Pevonia® continues to be a ...
(Date:8/20/2014)... 2014 (HealthDay News) -- Taking the widely ... dying from heart-related causes, a new study suggests. ... the findings require urgent confirmation, said the Danish researchers ... risk is small and that guidelines for the use ... information is available. One heart expert wasn,t surprised ...
Breaking Medicine News(10 mins):Health News:Re-Launched AbuseTreatmentCenters.net Offering New List of Substance Abuse Resources 2Health News:Integrative Nutrition Announces New Partnership with California Institute of Integral Studies 2Health News:Integrative Nutrition Announces New Partnership with California Institute of Integral Studies 3Health News:GranuFlo/NaturaLyte Case Remanded to State Court By Missouri Federal Judge, Baron and Budd Reports 2Health News:New Stem Cell Facial Unveiled at Botanica Day Spa 2Health News:New Stem Cell Facial Unveiled at Botanica Day Spa 3Health News:Antibiotic Might Raise Heart Risks for Some 2
... Organisation (WHO) Monday hailed the progress of governments of Western ... region needed greater effort to effectively control the disease. ... of detecting at least 70 percent of TB cases and ... Maaren, regional adviser for the health body's TB programme. ...
... miniature robot that can be inserted through an incision ... body. ,Researchers from Ritsumeikan University and the ... that is controlled remotely once placed inside the body. ... centimeters (0.79 inches) in length and one in diameter. ...
... that some patients who complete bariatric surgery can develop ... deficiency, called Wernicke encephalopathy. , The researchers ... about their conclusions by extensive survey of data relating ... surgery. , The syndrome - Wernicke encephalopathy ...
... inhaled anesthetics increase the number of amyloid plaques in ... of neurodegenerative diseases like Alzheimer's. ,Roderic Eckenhoff, ... Pennsylvania's Department of Anesthesia and Critical Care, and his ... edition of Neurobiology of Aging. ,Every year ...
... hardly 29 per cent of the asthmatic children surveyed had ... as a dangerous trend for not vaccinating their kids against ... officials have warned. ,Actually it has been warned ... fall victims to pneumonia or acute respiratory disease. Inactivated flu ...
... possibly hazardous chemicals called polybrominated diphenyl ethers (PBDEs). The ... and Technology and the Environmental Protection Agency of the ... clear how dangerous these PBDEs are, though some types ... is strikingly similar to that of PCBs, which are ...
Cached Medicine News:Health News:WHO Calls for Greater Efforts to Fight TB 2Health News:Inhaled Anesthetics Accelerate the Onset of Neurodegenerative Diseases Like Alzheimer's 2
RIA kit for the determination of autoantibodies to the TSH receptor (TSHR) in serum [with calibrators]....
ELISA kit for the determination of autoantibodies to the TSH receptor (TSHR) in serum....
Coated-Tube (CT) RIA kit for the determination of autoantibodies to the TSH receptor (TSHR) in serum...
RIA kit for the quantitative determination of autoantibodies to thyroid peroxidase (TPO) in serum....
Medicine Products: